Literature DB >> 23123985

Developing clinical guidelines for end-of-life care: blending evidence and consensus.

Trisha Dunning1, Sally Savage, Nicole Duggan, Peter Martin.   

Abstract

BACKGROUND: Developing clinical practice guidelines (CPGs) is challenging, particularly in areas that are difficult to research such as end-of-life care. AIM: To describe the process that staff in a large regional health-care service in Victoria, Australia, used to develop CPGs for managing diabetes at the end of life.
METHOD: An interdisciplinary advisory group was appointed, a structured literature review undertaken, personal illness accounts sourced, and a guiding philosophy formulated. Individual interviews were conducted with people with diabetes and their carers. Formative and summative evaluation was undertaken.
RESULTS: No level I or II evidence was identified. The interviews yielded important information about how people wanted their diabetes managed. Formative evaluation enabled stakeholders to participate in developing the CPGs. The summative evaluation confirmed the CPGs are easy to use and appropriate to clinical staff.
CONCLUSIONS: The CPG development process yielded the best current evidence on which to base care plans and person-centred CPGs.

Entities:  

Mesh:

Year:  2012        PMID: 23123985     DOI: 10.12968/ijpn.2012.18.8.397

Source DB:  PubMed          Journal:  Int J Palliat Nurs        ISSN: 1357-6321


  2 in total

1.  Use of Improving Palliative Care in the ICU (Intensive Care Unit) Guidelines for a Palliative Care Initiative in an ICU.

Authors:  Eluned Mun; Craig Nakatsuka; Lillian Umbarger; Ruth Ruta; Tracy Mccarty; Cynthia Machado; Clementina Ceria-Ulep
Journal:  Perm J       Date:  2017

Review 2.  Management of Diabetes in Long-term Care and Skilled Nursing Facilities: A Position Statement of the American Diabetes Association.

Authors:  Medha N Munshi; Hermes Florez; Elbert S Huang; Rita R Kalyani; Maria Mupanomunda; Naushira Pandya; Carrie S Swift; Tracey H Taveira; Linda B Haas
Journal:  Diabetes Care       Date:  2016-02       Impact factor: 19.112

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.